Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29190026 | 0.85 | HPGD (0.48) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL31430607 | 0.85 | HPGD (0.48) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL19071923 | 0.84 | VCAM1 (0.55) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL24901672 | 0.81 | HPGD (0.42) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL11965650 | 0.81 | HPGD (0.58) | HPGDVCAM1MAPTLMNAALDH1A1 | |
| SCHEMBL27212775 | 0.80 | VCAM1 (0.51) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL30158975 | 0.80 | VCAM1 (0.51) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL22696475 | 0.80 | HPGD (0.44) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL28679664 | 0.80 | HPGD (0.44) | HPGDVCAM1MAPTKDM4ELMNA | |
| SCHEMBL5470372 | 0.79 | HPGD (0.54) | HPGDVCAM1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2024-05-16 | — | — | US | disclosed |
| EP-3972964-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-30 | — | — | EP | disclosed |
| CN-113874380-A | Other heteroaromatic compounds with anti-RSV activity | 爱尔兰詹森科学公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2020234333-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020234333-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | MAVS, ZC3HAV1, RNASEH1 | HPGD 2037/4885VCAM1 1218/4885MAPT 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.